Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Retail has no power in this vote. Some unknown buyer of around 44M shares during the last offering has not filed who they are, and will not vote on the increase of the authorized. Whoever owns all of these shares wants the company to disclose all the good news they've been holding out on before they agree to a vote. This is one scenario, the other could just be the company stalling before a possible M&A.
Meeting postponed, what does this mean?
Seems this company has great tech, plenty of cash. Why are shareholders in revolt?
Will stock plunge on monday?
Almost selling for cash now
I am pretty sure that Fress is diamond hands wait and see he will be back soon. IMO
Lol jesus man he jumped the boat a while back
Hopefully you didn’t bail here. It’s been a few weeks and your girlfriend should set you free.
Any pop will likely be small since the main headlines have come and gone. Additionally they have to spend a lot more money and time to get phase 2b going.
This is going to take awhile to germinate and blossom. For now I’ll watch and look to take a position closer to an announcement of 2b data, which should be powered to be pivotal.
Murocman
The rest of the data from trials...
"The current findings support this potential, and we will continue to analyze additional incoming data from this trial which should allow us to better understand CRV431. We expect this additional data from the AMBITION trial in the near-term and will report it once we complete our analyses.”
https://finance.yahoo.com/news/hepion-pharmaceuticals-announces-positive-topline-120000659.html
What would be a catalyst for this to takeoff and when?
Murocman
This is crazy undervalued. Cash on hand 120M, no depth and Mcap only 115M. Added more again at 1.5x
What will be the share count?
HEPA has about 7-8 of those qualifications.
I obviously don't know enough about Hepion yet. Clearly, positive Phase 2a results increases the likelihood of a buyout. But I'm not convinced the article provides any indication of a buyout on the horizon for hepa.
Mostly was sure if there were actual "rumored news" that's causing the drop.
Welcome, lol
I'm with you
===================
$HEPA from a poster @ ST
Hepion will not get a quorum, because they refuse to say why they want 400m authorized shares, when they only have a $350m shelf.
Only a lunatic would go along with that, without being told anything at all about Hepion's plans.
Simple f'n math says that to exhaust that shelf you'd have to sell the 400m shares at about 87 cents each, unless they plan to exhaust the shelf and have a lot of the 400m left over, but they refuse to say that.
They refuse to talk about anything at all, but they're asking for a vote? A blind f'n vote? Who the hell is going to go along with that bullshit?
Screw that. It's f'n nuts!
Sure, they have bigger plans for CRV431, and the addition of a molecule to the pipeline, and those value drivers ought to translate to big gains in the stock price, but not if hundreds of millions of shares are issued at this severely retarded price.
NO QUORUM!!!
GOOD CALL: Maybe 1.6 next
Didnt take long
New to HEPA. Got in after hearing their amazing NASH results. Looking forward to their 2b trial.
Question, I'm assuming I'm just out of the loop. Why did the stock tank and not go up after meeting its Primary Endpoint? Never seen a stock go down after met P.E.
I see no relevant news, but I am brand new. Are they going to have a large share offering? Not sure what other reason there is for such a sell-off
Miss to hear from Fress need his positive vibes.
I have added a lot of shares the last weeks Diamond hands and patience.
What a rollover. We’ve been steamrolled.
WTF are you talking about? It's never been pumped, only dumped. This is purposely being held down for a reason. Company wants their quorum, but they're not going to get it.
Tried to warn ya'll. I'm Ferda Homies not Ferda hedgies.
HEPA got pumped and dumped and will do so again.
Maybe short this piggy to 1.53? Hell yea bro
Might find support at $1.55, if that breaks down watchout below
Where’s the bottom here. This is painful. They are just pounding this down and down.
Terrible red days , but I accumulated more shares.
Still avg. over $2 , but don´t you think it will be fine when I look on my account next year :) ?
Same $1.55-$1.68
Im On the bid
Perfect ATM, no worries
Good DD from the best "Fress"...
Lots of announcements from companies today about presentations at the upcoming EASL conference. Hepion will almost certainly be presenting something there, too. If so, we'll see whether they announce it tomorrow morning, or do like they did with the EASL presentation last August, with the PR on the same day as the presentation of CRV431 P1 results.
HEPA CRV431 is the most optimal antifibrotic drug in the clinic. The wide array of applications this drug can be used for can make HEPA 50- 100 Billion dollar company in the next 5 year years. No FDA approved drugs for NASH
The International Liver Congress 2021 will begin on Wednesday June 23 and ends on Saturday, June 26 2021 https://easl.eu/event/the-international-liver-congress-2021/
NASH is 35 Billion dollar market that will near 100 Billion next 5-10 years.
Hepion - Page S321 https://easl.eu/wp-content/uploads/2021/06/EASL_2021_-Version-1_new.pdf
Background and aims:The canonical experimental models (i.e. cellculture and rodents) for the study of Alcohol-related Liver Diseases(ALD) present limitations which impede the advancement of noveltherapies, particularly the difficulty in recapitulating the spectrum of pathological manifestations associated with the development/pro-gression of ALD in humans including steatosis, inflammation, hepatotoxicity, fibrosis and cirrhosis. The need to overcome this barrier to drug development underpins the current study. We describe the development of an immunocompetent ex-vivo humanmodel of ALD based on the culture of Precision Cut Liver Slices (PCLS)and their direct application for the assessment of the the Therapeutic effects of the cyclophilin inhibitor, CRV431.Method:Tumour-free liver specimens (‘healthy’or cirrhotic) we recollected from patients (n = 22) undergoing resection of livermetastasis. PCLS were made from the resected tissue, cultured forup to 5 days, and exposed to hepatotoxic insults: ethanol 50–250 mM, oleic/linoleic acids 0.1 mM, and LPS 10 µg/ml. The thera-peutic effects of 5 µM CRV431 were studied for the duration of theculture. Viability and cell death were evaluated by histology,cytokeratin 18 release, and ATP content. Steatosis was evaluated byOil-Red-O staining. Fibrosis was measured by gene expression,secretion and histology. Inflammatory cytokines were quantified byluminex. Mitochondrial fitness was evaluated by functional andmorphological assays.Results:The exposure of PCLS to ethanol for increasing time periods(up to 5 days) could mimic the clinical features of ALD. Early ethanolexposure was characterised by low overall cell death but increasedmitochondrial alterations. The addition of fatty acids and an acuteinflammatory hit (LPS) promoted steatohepatitis, inflammatorycytokine production and fibrosis. The cirrhotic PCLS were used toinvestigate tissue architecture and fibrotic processes in the context oflate stage chronic disease. PCLS treated with CRV431 maintainedgood viability, mitochondrial function, and low apoptosis over theculture duration. CRV431 also tempered inflammation in thepresence of LPS and induced a dramatic decrease in gene expressionand deposition of Collagen and Timp-1.Conclusion:In summary, we have developed a versatile immuno-competent platform which can reliably recapitulate the clinicalfeatures of ALD and have shown that it can be effectivelyemployed toassess the efficacy of novel immunomodulatory and anti-fibrotictherapeutic agents.PO-2331Past hospital contacts due to alcohol do not predict fibrosis stagein alcohol-related liver disease. A study of alcohol diagnoses andmorbidity in 18 years leading up to biopsy-proven liver fibrosis in462 patientsDitlev Rasmussen1, Maria Kjærgaard1, Katrine Prier Lindvig1,Mads Israelsen1, Kathrine Thorhauge1, Nikkolaj Christian Torp1,Stine Johansen1, Sönke Detlefsen2, Aleksander Krag1, Maja Thiele1.1Odense University Hospital, Departnemt of Gastroenterology andHepatology;2Odense University Hospital, Department of Pathology,DenmarkEmail: ditlev.nytoft.rasmussen@regionh.dk.Background and aims:Decompensated alcohol-related liver diseaseis preceded by several years of excessive drinking. Hospital contactsforalcohol problems are potential opportunities forearly detection ofcirrhosis. We aimed to investigate whether patients with biopsy-proven severe fibrosis and cirrhosis had more past hospital contactsdue to alcohol than alcohol-overusing patients with significant or minimal fibrosis.
Phase 2A data on CRV431 225mg between next week and the end of June. Last year they announced the day before the conference they where presenting. And as well as inclusion into Russell index!!
Phase CRV431 2A preliminary conclusions:
1.Reduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjects.
2.CRV431 in NASH Phase 2a Preliminary ConclusionsReduction in transaminases at 28 days signals early efficacy in F2/F3 NASH subjectsCRV431 concentration predicts reductions in serum alanine transaminase.
3.Trial Simulations suggest greater expected efficacy at 150 mg and 225 mg dose levels.
4.Bioinformatics with AI-POWR?reveal significant interactions with collagen regulating genes.
5.Confirmation of these effects will be fully evaluated using the 225 mg cohort and the final genomic, lipidomic, and biomarker data for a full simulation of the Phase 2b Trial.
AI-POWR™ Confers Strategic Advantages from Clinical Trials to Commercialization: A.Novel drug target selection B.Biomarker selection and validation C.Patient selection (-responder analysis) De-risk clinical trials D.Improve drug development efficiency with cost savings
HEPA molecule CRV431 for NASH is safer than MDGL & AKRO & HEPA Efficacy looks next level. These 2 companies MDGL & AKRO are both Billion dollar plus companies look for HEPA market cap to grow exponentially.
Key take away: In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
June 2021 Hepa Biz Presentation https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
Wait and see when $HEPA release news with Data very soon.
I expect them to come this month and when they comes we will be move fast.
First short term target is around $4 range.
Its already has price targets above $4 and $5 lol. Good stocks move up on fundamentals. Don't hope for price upgrades to turn a trade into profit. That's a sure way to lose money.
$HEPA
I think we see some new price targets over $8 and it will start a move.
Well I tried to warn everyone that would happen. No need to play this stinker HEPA when there is ol faithful providing plenty of volatility.
you know its a pos stock when massive institutional ownership keeps it cycling between 1.6 and 2.3. Needs to be part of some big health fund etf to get any traction.
$HEPA from a poster @ ST
Hepion will not get a quorum, because they refuse to say why they want 400m authorized shares, when they only have a $350m shelf.
Only a lunatic would go along with that, without being told anything at all about Hepion's plans.
Simple f'n math says that to exhaust that shelf you'd have to sell the 400m shares at about 87 cents each, unless they plan to exhaust the shelf and have a lot of the 400m left over, but they refuse to say that.
They refuse to talk about anything at all, but they're asking for a vote? A blind f'n vote? Who the hell is going to go along with that bullshit?
Screw that. It's f'n nuts!
Sure, they have bigger plans for CRV431, and the addition of a molecule to the pipeline, and those value drivers ought to translate to big gains in the stock price, but not if hundreds of millions of shares are issued at this severely retarded price.
NO QUORUM!!!
Explain to me what was so Terrible here. The only thing possible is the trepidation of the ASH coming next week. Makes no sense.
I just added more shares in $HEPA.
My avg. still over $2, but I am because I am sure we will be trading much much higher when data comes.
All we need is midastouch, added twice today..
Hepion shares fall after CRV431 mid-stage NASH study results
Jul. 13, 2021 8:32 AM ETHepion Pharmaceuticals, Inc. (HEPA)
By: Aakash Babu, SA News Editor
Hepion Pharmaceuticals (NASDAQ:HEPA) shares fall more than 7% premarket despite announcing that its CRV431 treatment met all primary endpoints in a mid-stage trial of patients with non-alcoholic steatohepatitis ("NASH").
The study was a Phase 2a randomized, multi-center, placebo controlled, single-blind trial designed to investigate once daily oral administration of CRV431 at doses of 75 mg and 225 mg administered as soft gelatin capsules to presumed F2 and F3 NASH subjects for 28 days.
CRV431 at both study doses was well tolerated, and there were no serious adverse events (“SAEs”), and the few adverse events (“AEs”) observed were mostly mild and unrelated to study drug, the company said.
Results showed reductions in liver transaminases, which indicate dose-related improvements in a key NASH biomarker.
Early indications of efficacy in the form of alanine aminotransferase (ALT) reductions were observed with both CRV431 dosing cohorts.
The percent ALT change from baseline to Day 28 numerically demonstrated a CRV431 versus placebo dose-response, the company said.
This is massive short covering. EDGX on the bid with huge orders trying to cover. Shorts were unable to cover earlier with the low volume.
Seeking Alpha is a giant POS!
Wow. Unlimited dumping. Where’s any retail buying. Looks like this could go much lower now. Ouch
How convenient LOL pump much?
Nothing terrible that I read. This stinks but people flipping for pennies right now. Not expected that’s for sure. Manipulation
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2150
|
Created
|
12/18/14
|
Type
|
Free
|
Moderators |
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
Currently trading at $2.2 due to a public offering of 44.000.000 shares $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
$HEPA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |